Skip to main content

Newsroom press releases

29/01/26 - 7:03

Diasorin has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL (128.56 KB)
Products Immunodiagnostic
Download

26/01/26 - 7:09

Diasorin signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel (131.63 KB)
Products Molecular
Download

28/12/25 - 18:48

Diasorin receives FDA 510(k) clearance and CLIA-waiver for its first assay, the 4-Plex Respiratory Panel, on the LIAISON NES Molecular Diagnostics platform (140.92 KB)
Products Molecular
Download

24/11/25 - 11:10

Diasorin submits the LIAISON PLEX Gastrointestinal Flex Assay to the U.S. FDA for 510(k) Clearance (128.44 KB)
Products Molecular
Download

18/11/25 - 6:30

Diasorin, in partnership with QIAGEN, unveils the next generation of the LIAISON QuantiFERON-TB Gold Plus II assay to deliver significant testing productivity and faster results in all Countries accepting the CE mark (147.94 KB)
Products Immunodiagnostic
Download

05/11/25 - 17:46

Diasorin’s Board of Directors approves results for the first 9 months of 2025. FY 2025 Guidance revised (255.77 KB)
Financial Data
Download

31/10/25 - 10:12

Diasorin receives 510(k) clearance for Simplexa COVID-19, Flu A/B & RSV Direct kit on the LIAISON MDX from the U.S. Food and Drug Administration (132.55 KB)
Products Molecular
Download

19/09/25 - 9:34

Diasorin launches LIAISON® TSH-R Ab, an immunodiagnostic assay to improve Graves’ Disease diagnosis, in all countries accepting CE mark (130.17 KB)
Products Immunodiagnostic
Download

08/09/25 - 11:16

New evidence on MeMed BV's role in supporting emergency medicine clinical decisions unveiled at ACEP 2025 (136.64 KB)
Products Immunodiagnostic
Download

31/07/25 - 16:22

Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed (238.17 KB)
Financial Data
Download

02/07/25 - 8:10

Diasorin submits the LIAISON NES® Point-of-Care molecular diagnostics system and 4-plex Respiratory Panel to the FDA for 510(k) Clearance and CLIA Waiver (133.82 KB)
Products Molecular
Download

07/06/25 - 12:25

Diasorin announces 510(k) clearance for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (143.05 KB)
Products Molecular
Download

06/05/25 - 17:41

Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidance (268.56 KB)
Financial Data
Download

18/04/25 - 18:11

Diasorin receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX® (161.29 KB)
Products
Download

18/03/25 - 11:54

Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark (126.65 KB)
Products Molecular
Download

14/03/25 - 16:29

The Board of Directors of Diasorin SpA approves FY2024 Results with revenues and net profit in expansion compared to Previous Year; Proposed Ordinary Dividend of € 1.20 per share (239.79 KB)
Financial Data
Download

11/11/24 - 7:38

Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (122.52 KB)
Products Molecular
Download

05/11/24 - 16:27

Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)
Financial Data
Download

27/09/24 - 7:35

Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay (559.45 KB)
Products Molecular
Download

09/09/24 - 13:11

Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)
Products Immunodiagnostic
Download

29/07/24 - 15:55

DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)
Financial Data
Download

16/07/24 - 8:31

Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)
Products Molecular
Download

05/06/24 - 5:07

Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)
Products Molecular
Download

16/05/24 - 19:56

Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)
Products Molecular
Download

10/05/24 - 15:21

Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)
Financial Data
Download

15/03/24 - 13:35

The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)
Financial Data
Download

13/03/24 - 10:23

Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)
Products Molecular
Download

03/03/24 - 19:32

Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)
Products Molecular
Download

25/01/24 - 7:48

Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)
Products Immunodiagnostic
Download

15/12/23 - 17:38

Diasorin Board of Directors approves 2024-2027 Business Plan (294.02 KB)
Financial Data
Download

06/11/23 - 15:44

Diasorin and Gilead Sciences collaborate to develop a Fully Automated Diagnostic Assay for Hepatitis Delta Virus on Diasorin’s LIAISON XL® for the U.S. Market (506.97 KB)
Products Immunodiagnostic
Download

03/11/23 - 15:51

Third Quarter results confirm guidance for Fiscal Year 2023 (822.89 KB)
Financial Data
Download

27/07/23 - 13:18

Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed (598.06 KB)
Financial Data
Download

17/07/23 - 7:03

DiaSorin launches the LIAISON® Legionella Urinary Ag assay in all countries accepting the CE Mark to improve diagnosis of legionnaires’ disease (510.4 KB)
Products Immunodiagnostic
Download

13/06/23 - 15:18

DiaSorin launches the LIAISON® B·R·A·H·M·S MR-proADM™ assay in all countries accepting the CE Mark (578.05 KB)
Products Immunodiagnostic
Download

09/05/23 - 11:56

Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023 (675.79 KB)
Financial Data
Download

27/03/23 - 14:38

Dividend coupon date correction (493.46 KB)
Financial Data
Download

27/03/23 - 13:35

REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE (334.51 KB)
Financial Data
Download

17/03/23 - 22:05

DiaSorin Simplexa COVID Flu assay received U.S. FDA 510(K) clearance (155.02 KB)
Products Molecular
Download

09/11/22 - 7:04

DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)
Products Molecular
Download

07/11/22 - 7:12

DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)
Products Molecular
Download

27/10/22 - 13:44

Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
Financial Data
Download

05/10/22 - 6:37

DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)
Products Molecular
Download

14/09/22 - 0:29

DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)
Products Molecular
Download

03/08/22 - 12:26

Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
Financial Data
Download

14/07/22 - 20:00

DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)
Products Immunodiagnostic
Download

20/05/22 - 7:08

DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)
Products Molecular
Download

06/05/22 - 16:45

Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
Financial Data
Download

16/03/22 - 17:39

DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)
Financial Data
Download

08/03/22 - 7:13

DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)
Products Molecular
Download

13/01/22 - 7:24

DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)
Products Molecular
Download

16/12/21 - 22:47

DiaSorin 2022-2025 Strategic Plan (552.15 KB)
Financial Data
Download

30/11/21 - 19:10

DiaSorin confirms effectiveness of its Molecular Diagnostic tests in light of new Omicron SARS-CoV-2 Variant (307.83 KB)
Products Molecular
Download

29/11/21 - 7:06

DiaSorin receives FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay for use on the LIAISON® XS Analyzer (437.79 KB)
Products Immunodiagnostic
Download

23/11/21 - 7:10

DiaSorin launches LIAISON® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark (412.77 KB)
Products Immunodiagnostic
Download

11/11/21 - 16:56

DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021 (862.48 KB)
Financial Data
Download

18/09/21 - 8:16

DiaSorin CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test (407.21 KB)
Products Molecular
Download

30/07/21 - 12:57

DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex (774.36 KB)
Financial Data
Download

15/06/21 - 6:56

DiaSorin launches the first fully automated CLIA high-throughput solution for diagnosing Hepatitis E (307.58 KB)
Products Immunodiagnostic
Download

25/05/21 - 7:03

DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection (402.64 KB)
Products Immunodiagnostic
Download

21/05/21 - 7:02

DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2 (393.69 KB)
Products Molecular
Download

20/05/21 - 8:27

DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market (506.2 KB)
Products Immunodiagnostic
Download

14/05/21 - 16:10

DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021 (756.07 KB)
Financial Data
Download

28/04/21 - 17:46

DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028 (529.64 KB)
Financial Data
Download

28/04/21 - 7:54

DiaSorin announces its intention to offer € 500 million senior unsecured equity-linked bonds due 2028 (563.02 KB)
Financial Data
Download

21/04/21 - 7:02

DiaSorin, in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology (621.42 KB)
Products Immunodiagnostic
Download

20/04/21 - 18:58

DiaSorin launches the LIAISON® IQ with a first test that detects IgG antibodies against SARS-COV-2 in markets accepting the CE Mark (403.5 KB)
Products Immunodiagnostic
Download

30/03/21 - 7:01

DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test (661.47 KB)
Products Immunodiagnostic
Download

29/03/21 - 7:02

DiaSorin has obtained FDA Emergency Use Authorization for its LIAISON® SARS-CoV-2 Ag for COVID-19 testing in the U.S. (494.1 KB)
Products Immunodiagnostic
Download

11/03/21 - 16:37

Dividend coupon date correction (414.99 KB)
Financial Data
Download

11/03/21 - 15:31

Revenues, Profitability and Cash Flow Generation hit record highs in 2020 (748.06 KB)
Financial Data
Download

23/02/21 - 6:11

DiaSorin obtained FDA approval for two additional serology tests for Lyme Disease in the U.S. market (413.92 KB)
Products Immunodiagnostic
Download

11/01/21 - 18:43

DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG test (418.29 KB)
Products Immunodiagnostic
Download

29/12/20 - 18:22

DiaSorin has received BARDA Funding in support of submitting the SIMPLEXA COVID-19 Direct Kit for 510(k) clearance (400.67 KB)
Products Molecular
Download

01/12/20 - 6:33

DiaSorin received FDA approval for its LIAISON® XL MUREX HIV Ab/Ag assay, completing the Hepatitis and Retrovirus offer in the US market (566.6 KB)
Products Immunodiagnostic
Download

11/11/20 - 12:41

North America growth drives up revenues and profitability in the first 9 months of 2020 (805.25 KB)
Financial Data
Download

26/10/20 - 18:30

DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients (414.59 KB)
Products Immunodiagnostic
Download

01/10/20 - 7:45

DiaSorin received FDA approval on 6 Hepatitis B tests, completing its Hepatitis offer in the US market (395.31 KB)
Products Immunodiagnostic
Download

01/10/20 - 7:32

DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market (488.09 KB)
Products Immunodiagnostic
Download

16/09/20 - 7:25

DiaSorin Simplexa™ COVID-19 Direct molecular test CE marked for saliva specimens (477.67 KB)
Products Molecular
Download

07/09/20 - 18:22

FDA approval of Simplexa flu A_B & RSV Direct Gen II Assay (400.26 KB)
Products Molecular
Download

06/08/20 - 7:25

DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test for the dosage of testosterone (391.91 KB)
Products Immunodiagnostic
Download

30/07/20 - 13:16

North America business growth drives Group revenues and profitability in H1 2020 (735.54 KB)
Financial Data
Download

09/07/20 - 7:27

DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study (399.63 KB)
Products Immunodiagnostic
Download

07/07/20 - 7:22

DiaSorin CE marks their new Simplexa Flu A/B & RSV Direct Gen II Assay to run with the Simplexa COVID-19 Direct assay (490.1 KB)
Products Molecular
Download

30/06/20 - 7:25

DiaSorin announces the launch of its new LIAISON® SARS-COV-2 IgM test, a new fully automated serology kit available in Europe and in the U.S. to identify the immediate response to SARS-COV-2 in COVID-19 patients (397.37 KB)
Products Immunodiagnostic
Download

12/06/20 - 7:30

DiaSorin has CE marked its molecular's Simplexa™ Congenital CMV Direct Assay (478.6 KB)
Products Molecular
Download

03/06/20 - 14:16

The LIAISON® SARS-COV-2 S1/S2 IgG test received the approval for the commercialization in Brazil from ANVISA (397.21 KB)
Products Immunodiagnostic
Download

18/05/20 - 11:28

The LIAISON® SARS-COV-2 S1S2 IgG test is the first to receive the approval from Health Canada (308.26 KB)
Products Immunodiagnostic
Download

13/05/20 - 13:15

DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic (741.65 KB)
Financial Data
Download

25/04/20 - 16:49

DiaSorin - FDA EUA and BARDA funding for SARS-CoV-2 IgG (403.66 KB)
Products Immunodiagnostic
Download

17/04/20 - 18:25

DiaSorin has CE marked its SARS-COV-2 IgG serology kit for COVID-19 (464.49 KB)
Products Immunodiagnostic
Download

07/04/20 - 7:14

IgG test to detect immune response to SARS-CoV-2 (394.92 KB)
Products Immunodiagnostic
Download

20/03/20 - 7:28

DiaSorin COVID-19 test has received FDA Emergency Use Authorization (397.04 KB)
Products Molecular
Download

13/03/20 - 17:16

DiaSorin received BARDA funding to develop a rapid COVID-19 test (403.34 KB)
Products Molecular
Download

11/03/20 - 13:43

DiaSorin - Cash flow generation and net profit hit record highs in 2019 (919.6 KB)
Financial Data
Download

10/03/20 - 8:20

DiaSorin - Development of Coronavirus test (404.03 KB)
Products Molecular
Download

16/12/19 - 14:10

Diasorin receives FDA clearance for Simplexa VZV Swab Direct Molecular assay (571.47 KB)
Products Molecular
Download

27/11/19 - 7:59

DIASORIN LAUNCHES THE LIAISON QUANTIFERON-TB GOLD PLUS ASSAY IN PARTNERSHIP WITH QIAGEN IN THE US MARKET (531.97 KB)
Products Immunodiagnostic
Download

11/11/19 - 9:46

DIASORIN LAUNCHES PRIMER PAIR FOR CANDIDA AURIS IN THE US MARKET (159.93 KB)
Products Molecular
Download

06/11/19 - 13:00

Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019 (621.09 KB)
Financial Data
Download

30/10/19 - 9:55

DIASORIN LAUNCHES LIAISON® XL ZIKA CAPTURE IgM II TEST FOR THE DETECTION OF ZIKA VIRUS IN THE US MARKET (579.27 KB)
Products Immunodiagnostic
Download

22/10/19 - 14:10

DIASORIN LAUNCHES LIAISON HCV TEST FOR HEPATITIS C DIAGNOSIS IN THE US MARKET (358.37 KB)
Products Immunodiagnostic
Download

24/09/19 - 10:10

DiaSorin launches VZV Direct molecular test in Europe (369.67 KB)
Products Molecular
Download

31/07/19 - 13:00

DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability. (687.57 KB)
Financial Data
Download

10/06/19 - 18:23

DiaSorin presents its 2019-2022 Industrial Plan (548.2 KB)
Financial Data
Download

29/05/19 - 15:06

DiaSorin launches VZV DIRECT molecular test in the United States (360.87 KB)
Products Molecular
Download

09/05/19 - 13:14

DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019 (728.82 KB)
Financial Data
Download

06/05/19 - 15:19

DiaSorin launches ELASTASE-1 test for the diagnosis of chronic exocrine pancreatitis on LIAISON XL (416.77 KB)
Products Immunodiagnostic
Download

03/04/19 - 10:32

DiaSorin launches the anaemia panel on Liaison XL in Europe (416.47 KB)
Products Immunodiagnostic
Download

14/03/19 - 14:16

Growth in revenues, profitability and net profit in 2018 (1.03 MB)
Financial Data
Download

31/01/19 - 22:30

DiaSorin launches FDA-cleared LIAISON Calprotectin test in the US market (528.02 KB)
Products Immunodiagnostic
Download

03/01/19 - 13:30

DiaSorin launches Simplexa Bordetella Direct Molecular test in the United States (428.56 KB)
Products Molecular
Download

21/12/18 - 11:30

DiaSorin launches 3 new primer pairs for use in molecular testing (438.25 KB)
Products Molecular
Download

04/12/18 - 8:00

DiaSorin's stocks listed in the FTSE MIB (464.63 KB)
Financial Data
Download

19/11/18 - 15:00

DiaSorin launches Simplexa Group B Strep Direct molecular assay in the United States (435.43 KB)
Products Molecular
Download

07/11/18 - 13:00

DiaSorin Group reports growth in revenues and net profit in the first nine months of 2018 (961.72 KB)
Financial Data
Download

17/10/18 - 11:51

DiaSorin launches Simplexa Group B Strep Direct molecular assay in the european market (147.78 KB)
Products Molecular
Download

12/10/18 - 11:47

DiaSorin launches Simplexa VZV Direct molecular assay in the european market (444.81 KB)
Products Molecular
Download

17/09/18 - 11:28

DiaSorin launches the new LIASON quantiFERON-TB Gold Plus assay as an aid for latent tuberculosis detection in partnership with Qiagen (753.85 KB)
Products Immunodiagnostic
Download

07/08/18 - 8:45

Communication on total amount of voting rights (305.24 KB)
Financial Data
Download

02/08/18 - 12:45

The Board of Directors approves the results for the first half of 2018 (883.1 KB)
Financial Data
Download

27/07/18 - 12:00

DiaSorin launches Hepatitis Delta (HDV) test on LIAISON XL platform (735.03 KB)
Products Immunodiagnostic
Download

03/07/18 - 18:30

Conclusion treasury shares buy-back plan (397.33 KB)
Financial Data
Download

03/07/18 - 18:30

Annex 3F (treasury shares buy back July 2018) (6.59 KB)
Financial Data
Download

03/07/18 - 18:30

Report treasury shares buy-back (287.99 KB)
Financial Data
Download

03/07/18 - 18:30

Annex 3F (treasury shares buy back June 2018) (8.69 KB)
Financial Data
Download

29/06/18 - 18:15

Weekly report treasury shares buy-back (290.62 KB)
Financial Data
Download

22/06/18 - 20:30

Weekly report treasury shares buy-back (290.6 KB)
Financial Data
Download

15/06/18 - 21:00

Weekly report treasury shares buy-back (290.62 KB)
Financial Data
Download

12/06/18 - 14:15

DiaSorin introduces primer pair reagents for use in molecular testing: Anaplasma phagocytophilum, Ehrlichia e Babesia (445.17 KB)
Products Molecular
Download

08/06/18 - 23:15

Weekly report treasury shares buy-back (290.24 KB)
Financial Data
Download

04/06/18 - 13:15

Annex 3F (treasury shares buy back May 2018) (8.54 KB)
Financial Data
Download

01/06/18 - 20:15

Weekly report treasury shares buy-back (290.38 KB)
Financial Data
Download

25/05/18 - 22:30

Weekly report treasury shares buy-back (289.97 KB)
Financial Data
Download

19/05/18 - 1:45

Weekly report treasury shares buy-back (289.76 KB)
Financial Data
Download

11/05/18 - 20:15

Weekly report treasury shares buy-back (290.77 KB)
Financial Data
Download

08/05/18 - 14:30

The DiaSorin Group reports growth in revenues and profitability in the first quarter 2018 (832.84 KB)
Financial Data
Download

03/05/18 - 20:15

Start up treasury shares buy-back plan (354.27 KB)
Financial Data
Download

24/04/18 - 14:00

Annex 3F (treasury shares buy back) (7.77 KB)
Financial Data
Download

23/04/18 - 18:30

Annual General Meeting 2018 (589.65 KB)
Financial Data
Download

19/04/18 - 21:15

Conclusion treasury shares buy-back plan (397.59 KB)
Financial Data
Download

19/04/18 - 21:00

Weekly report treasury shares buy-back (289.29 KB)
Financial Data
Download

13/04/18 - 20:30

Weekly report treasury shares buy-back (290.07 KB)
Financial Data
Download

06/04/18 - 19:45

Weekly report treasury shares buy-back (288.33 KB)
Financial Data
Download

05/04/18 - 12:00

DiaSorin receives FDA clearance for the LIAISON BRAHMS PCT II GEN assay to detect severe bacterial infections (e.g. Sepsis) (737.88 KB)
Products Immunodiagnostic
Download

04/04/18 - 20:00

Start up treasury shares buy-back plan (346.04 KB)
Financial Data
Download

28/03/18 - 18:45

DiaSorin earns FDA clearence extending sample claims for Simplexa HSV 1 & 2 direct molecular test (442.69 KB)
Products Molecular
Download

07/03/18 - 15:30

DiaSorin: FY 2017 Results (1.14 MB)
Financial Data
Download

30/01/18 - 11:45

DiaSorin signs an agreement with the Italian Tax Authority granting tax relief under the Italian Patent Box regime (574.68 KB)
Financial Data
Download

12/12/17 - 13:15

DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test (426.89 KB)
Products Molecular
Download

09/11/17 - 14:15

GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)
Financial Data
Download

29/09/17 - 15:00

DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)
Financial Data
Download

21/09/17 - 12:45

DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit (738.62 KB)
Products Molecular
Download

03/08/17 - 14:45

DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)
Financial Data
Download

28/07/17 - 14:45

DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS (427.51 KB)
Products Molecular
Download

10/07/17 - 13:30

DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP (197.68 KB)
Products Molecular
Download

26/06/17 - 9:45

DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)
Financial Data
Download

23/05/17 - 11:45

DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders (735.43 KB)
Products Immunodiagnostic
Download

16/05/17 - 13:00

DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality (429.25 KB)
Products Immunodiagnostic
Download

08/05/17 - 19:30

DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)
Financial Data
Download

27/04/17 - 18:45

DiaSorin - Annual General Meeting 2016 (421.04 KB)
Financial Data
Download

21/04/17 - 18:45

DiaSorin receives authorization for the distribution of Zika IgM test in Europe (349.09 KB)
Products Immunodiagnostic
Download

06/04/17 - 18:00

DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test (376.16 KB)
Products Immunodiagnostic
Download

08/03/17 - 15:30

The Board of Directors approves the results for FY'16 (1.13 MB)
Financial Data
Download

21/02/17 - 11:30

DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market (430.86 KB)
Products Molecular
Download

26/01/17 - 12:45

DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE (140.98 KB)
Products Immunodiagnostic
Download

19/12/16 - 10:00

Co-optation of a Director (333.18 KB)
Financial Data
Download

10/11/16 - 1:00

DIASORIN GROUP REPORTS CONTINUED GROWTH IN REVENUES AND PROFITABILITY IN THE THIRD QUARTER 2016 (1.05 MB)
Financial Data
Download

02/11/16 - 1:00

DIASORIN LAUNCHES ITS FIRST MOLECULAR TEST WITH THE NEW BUSINESS DIVISION, DIASORIN MOLECULAR: THE NEW SIMPLEXA C. DIFFICILE DIRECT MOLECULAR TEST (141.53 KB)
Products Molecular
Download

22/08/16 - 2:00

DIASORIN PARTNERS WITH HHS TO FACE THE ZIKA EMERGENCY (158.39 KB)
Products Immunodiagnostic
Download

04/08/16 - 2:00

The Board of Directors approves results for H1'16 (697.16 KB)
Financial Data
Download

28/07/16 - 2:00

DiaSorin starts selling Vitamin D in Japan (724.4 KB)
Products Immunodiagnostic
Download

14/07/16 - 2:00

DiaSorin increases diagnostic test menu for molecular screening of Acute Myeloid Leukemia (278.18 KB)
Products Molecular
Download

10/06/16 - 2:00

Weekly report treasury shares buy-back (289.83 KB)
Financial Data
Download

10/06/16 - 2:00

Conclusion buy-back plan (367.77 KB)
Financial Data
Download

07/06/16 - 2:00

DiaSorin launches the new Helicobacter pylori IgG CLIA test (518.61 KB)
Products Immunodiagnostic
Download

03/06/16 - 2:00

Weekly report treasury shares buy-back (290.21 KB)
Financial Data
Download

30/05/16 - 2:00

Notice filing By-Laws and publication operating procedures for loyalty shares (277.79 KB)
Financial Data
Download

27/05/16 - 2:00

Weekly report treasury shares buy-back (289.34 KB)
Financial Data
Download

20/05/16 - 2:00

Weekly report treasury shares buy-back (290.09 KB)
Financial Data
Download

12/05/16 - 2:00

Start up treasury shares buy-back plan (305.9 KB)
Financial Data
Download

09/05/16 - 2:00

The Board of Directors approves the results for Q1'16 (632.78 KB)
Financial Data
Download

28/04/16 - 2:00

Shareholders' Meeting FY 2015 (365.15 KB)
Financial Data
Download

09/03/16 - 1:00

The Board of Directors approves the results for FY'15 (785.08 KB)
Financial Data
Download

11/11/15 - 1:00

The Board of Directors approves the results for Q3'15 (778.06 KB)
Financial Data
Download

09/09/15 - 2:00

DiaSorin launches the two fastest molecular diagnostic tests in the world to detect fulminant leukemias (229.24 KB)
Products Molecular
Download

30/07/15 - 2:00

H1'15 Results (777.06 KB)
Financial Data
Download

28/05/15 - 2:00

DiaSorin launches the test for Campylobacter (241.86 KB)
Products Immunodiagnostic
Download

12/05/15 - 2:00

The Board of Directors approves the results for Q1'15 (553.96 KB)
Financial Data
Download

29/04/15 - 2:00

DiaSorin - launches the test for Brahms-Sepsis (506.96 KB)
Products Immunodiagnostic
Download

22/04/15 - 2:00

The Board of Directors approves the 2015-2017 plan that will be presented at the Investor Day (141.85 KB)
Financial Data
Download

22/04/15 - 2:00

Shareholders' meeting approves FY Results 2014 (105.93 KB)
Financial Data
Download

14/04/15 - 2:00

DiaSorin launches the tests for Bordetella pertussis (187.11 KB)
Products Immunodiagnostic
Download

10/04/15 - 2:00

Investor Day-save the date (107.93 KB)
Financial Data
Download

03/03/15 - 1:00

The Board of Directors approves the results for FY'14 (783.03 KB)
Financial Data
Download

14/01/15 - 1:00

DiaSorin launches the test for Calprotectin (259.67 KB)
Products Immunodiagnostic
Download

16/12/14 - 1:00

FDA approves 1,25 Vitamin D in the US market (239.73 KB)
Products Immunodiagnostic
Download

09/12/14 - 1:00

DiaSorin launches its first onco-hematology test on LIAISON Iam: the BCR-ABL (265.26 KB)
Products Immunodiagnostic
Download

14/11/14 - 1:00

The Board of Directors approves the results for Q3'14 (785.42 KB)
Financial Data
Download

07/10/14 - 2:00

DiaSorin launches the test for HIV HT on LIAISON (267.4 KB)
Products Immunodiagnostic
Download

18/09/14 - 2:00

DiaSorin launches the stool test for Adenovirus on LIAISON (251.93 KB)
Products Immunodiagnostic
Download

01/08/14 - 2:00

The Board of Directors approves the results for H1'14 (812.25 KB)
Financial Data
Download

22/07/14 - 2:00

DIASORIN CONFIRMS ITS ELIGIBILITY FOR THE PEA-PME (148.49 KB)
Financial Data
Download

30/06/14 - 2:00

DiaSorin launches the test for Herpes Simplex 1 and 2 on LIAISON IAM (250.1 KB)
Products Immunodiagnostic
Download

03/06/14 - 2:00

DiaSorin launches the test for Vitamin D 1,25 on LIAISON (265.57 KB)
Products Immunodiagnostic
Download

09/05/14 - 2:00

The Board of Directors approves the results for Q1'14 (573.05 KB)
Financial Data
Download

23/04/14 - 2:00

Shareholders' meeting approves FY Results 2013 (107.65 KB)
Financial Data
Download

06/03/14 - 1:00

The Board of Directors approves the results for FY'13 (753.73 KB)
Financial Data
Download

18/02/14 - 1:00

DiaSorin launches the new test for PTH on LIAISON (597.92 KB)
Products Immunodiagnostic
Download

11/02/14 - 1:00

DiaSorin launches the test for Rotavirus on stool sample (573.97 KB)
Products Immunodiagnostic
Download

24/01/14 - 1:00

DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in China (579.02 KB)
Products Immunodiagnostic
Download

09/01/14 - 1:00

DiaSorin launches the test for Cytomegalovirus on LIAISON IAM (174.61 KB)
Products Immunodiagnostic
Download

08/11/13 - 1:00

The Board of Directors approves the Q3'13 Results (766.57 KB)
Financial Data
Download

25/10/13 - 2:00

DiaSorin launches the EHEC Toxins test on stool samples (610.05 KB)
Products Immunodiagnostic
Download

10/10/13 - 2:00

DiaSorin launches the test for IgG to Trypanosoma Cruzi (Chagas) (615.28 KB)
Products Immunodiagnostic
Download

24/09/13 - 2:00

DiaSorin launches the hCG test on its LIAISON XL in the US (599.75 KB)
Products Immunodiagnostic
Download

01/08/13 - 2:00

The Board of Directors approves the results for the H1 '13 (386.67 KB)
Financial Data
Download

24/07/13 - 2:00

DiaSorin launches the new test for Toxoplasmosis on LIAISON IAM (490.89 KB)
Products
Download

11/07/13 - 2:00

DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in Brazil (113.84 KB)
Products Immunodiagnostic
Download

28/06/13 - 2:00

DiaSorin launches the test of Chlamydia Trachomatis IgG and IgA on LIAISON (78.13 KB)
Products Immunodiagnostic
Download

20/06/13 - 2:00

DiaSorin launches the new test for Parvovirus on LIAISON IAM (488.24 KB)
Products Immunodiagnostic
Download

10/05/13 - 2:00

The Board of Directors approves the results for Q1'13 (763.61 KB)
Financial Data
Download

02/05/13 - 2:00

Compensation Commitee-Errata corrige (179.38 KB)
Financial Data
Download

22/04/13 - 2:00

Shareholders' meeting approves FY Results 2012 (57.22 KB)
Financial Data
Download

17/04/13 - 2:00

FDA approves the Aldosterone assay (439.58 KB)
Products Immunodiagnostic
Download

08/03/13 - 1:00

The BoD approves FY 2012 results (477.24 KB)
Financial Data
Download

07/03/13 - 1:00

Notification of changes in share capital (46.86 KB)
Financial Data
Download

07/03/13 - 1:00

Notice availability By-Laws (36.87 KB)
Financial Data
Download

07/02/13 - 1:00

Clostridium difficile on LIAISON (available outside the US and Canada only) (79.83 KB)
Products Immunodiagnostic
Download

07/02/13 - 1:00

Notification of changes in share capital (46.89 KB)
Financial Data
Download

07/02/13 - 1:00

Notice availability By-Laws (139.13 KB)
Financial Data
Download

30/01/13 - 1:00

The Board of Directors approves the results for the FY '12 (477.24 KB)
Financial Data
Download

29/01/13 - 1:00

Aldosterone on LIAISON (available outside the US and Canada only) (76.47 KB)
Products Immunodiagnostic
Download

20/12/12 - 1:00

Shareholders' meeting (55.42 KB)
Financial Data
Download

07/11/12 - 1:00

The BoD approves Q3'12 results (280.42 KB)
Financial Data
Download

03/08/12 - 2:00

The BoD approves H1'12 results (279.41 KB)
Financial Data
Download

27/06/12 - 2:00

Notification of changes in share capital (335.97 KB)
Financial Data
Download

11/05/12 - 2:00

The BoD approves Q1'12 results (122.04 KB)
Financial Data
Download

23/04/12 - 2:00

2011 statutory financial statement approval (182.29 KB)
Financial Data
Download

10/04/12 - 2:00

Measles and Mumps IgM on LIAISON (available outside the US and Canada only) (43.59 KB)
Products Immunodiagnostic
Download

02/04/12 - 2:00

Helicobacter Pylori on stool on LIAISON (available outside the US and Canada only) (43.85 KB)
Products Immunodiagnostic
Download

30/03/12 - 2:00

Financial calendar update (176.51 KB)
Financial Data
Download

22/03/12 - 1:00

Stock options to employees (175.38 KB)
Financial Data
Download

09/03/12 - 1:00

The BoD approves FY 2011 results (357.11 KB)
Financial Data
Download

07/03/12 - 1:00

Notification of changes in share capital (46.84 KB)
Financial Data
Download

09/02/12 - 1:00

Notice of change in share capital (46.97 KB)
Financial Data
Download

02/02/12 - 1:00

FDA clearance for 25 OH Vitamin D on LIAISON (180.35 KB)
Products Immunodiagnostic
Download

27/01/12 - 1:00

2012 Financial calendar update (177.74 KB)
Financial Data
Download

25/01/12 - 1:00

Dividend distribution in June (115.61 KB)
Financial Data
Download

13/01/12 - 1:00

2012 Financial calendar (176.51 KB)
Financial Data
Download

12/01/12 - 1:00

New anti HBs II (available outside the US and Canada only) (196.83 KB)
Products Immunodiagnostic
Download

23/12/11 - 1:00

Financial instruments to employees (57.22 KB)
Financial Data
Download

19/12/11 - 1:00

Clostridium Difficile toxins A and B in stool on LIAISON (available outside the US and Canada only) (192.66 KB)
Products Immunodiagnostic
Download

19/11/11 - 1:00

Buy-back plan (35.47 KB)
Financial Data
Download

18/11/11 - 1:00

Financial instruments to employees (56.82 KB)
Financial Data
Download

11/11/11 - 1:00

The BoD approves Q3'11 results (334.35 KB)
Financial Data
Download

28/10/11 - 2:00

Buy-back plan (103.99 KB)
Financial Data
Download

25/10/11 - 2:00

Buy-back plan (104.72 KB)
Financial Data
Download

18/10/11 - 2:00

Buy-back plan (136.18 KB)
Financial Data
Download

17/10/11 - 2:00

2011-2015 Business Plan: a new business wave (195.1 KB)
Financial Data
Download

04/10/11 - 2:00

Buy-back plan (204.92 KB)
Financial Data
Download

31/08/11 - 2:00

2011 Financial calendar update (176.4 KB)
Financial Data
Download

03/08/11 - 2:00

The BoD approves H1'11 results (324.48 KB)
Financial Data
Download

11/07/11 - 2:00

Voluntarily removal from the STAR segment (194.93 KB)
Financial Data
Download

13/05/11 - 2:00

The BoD approves Q1'11 results (307.28 KB)
Financial Data
Download

28/04/11 - 2:00

The Ordinary Shareholders' meeting approves the 2010 statutory financial statements and the dividend distribution (175.61 KB)
Financial Data
Download

16/03/11 - 1:00

The BoD approves FY'10 results (368.28 KB)
Financial Data
Download

16/03/11 - 1:00

Dividend information amendment (159.83 KB)
Financial Data
Download

28/02/11 - 1:00

2011 Financial calendar update (179.92 KB)
Financial Data
Download

19/02/11 - 1:00

Notice of change in share capital (5.28 KB)
Financial Data
Download

18/02/11 - 1:00

Buy-back plan (134.06 KB)
Financial Data
Download

17/02/11 - 1:00

Financial instruments to employees (56.37 KB)
Financial Data
Download

16/02/11 - 1:00

Buy-back plan (105.2 KB)
Financial Data
Download

15/02/11 - 1:00

Buy-back plan (91.38 KB)
Financial Data
Download

14/02/11 - 1:00

The BoD approves Q4'10 results (161 KB)
Financial Data
Download

31/01/11 - 1:00

Buy-back plan (105.05 KB)
Financial Data
Download

29/01/11 - 1:00

Buy-back plan (105.2 KB)
Financial Data
Download

28/01/11 - 1:00

Buy-back plan (105.04 KB)
Financial Data
Download

27/01/11 - 1:00

Buy-back plan (105.04 KB)
Financial Data
Download

26/01/11 - 1:00

FDA approves the LIAISON XL (194.2 KB)
Products Immunodiagnostic
Download

25/01/11 - 1:00

Buy-back plan (105.22 KB)
Financial Data
Download

24/01/11 - 1:00

Buy-back plan (104.72 KB)
Financial Data
Download

21/01/11 - 1:00

Buy-back plan (105.05 KB)
Financial Data
Download

20/01/11 - 1:00

Buy-back plan (91.39 KB)
Financial Data
Download

19/01/11 - 1:00

Buy-back plan (105.31 KB)
Financial Data
Download

18/01/11 - 1:00

Buy-back plan (35.47 KB)
Financial Data
Download

17/01/11 - 1:00

Buy-back plan (134.01 KB)
Financial Data
Download

16/01/11 - 1:00

2011 Financial calendar (179.49 KB)
Financial Data
Download

22/12/10 - 1:00

2011 Financial calendar (180.28 KB)
Financial Data
Download

20/12/10 - 1:00

Dividend may be distributed in June (445.78 KB)
Financial Data
Download

02/12/10 - 1:00

Comment on position Paper on Vitamin D (53.46 KB)
Products Immunodiagnostic
Download

24/11/10 - 1:00

Change in share capital (46.85 KB)
Financial Data
Download

18/11/10 - 1:00

Financial instruments to employees (48.33 KB)
Financial Data
Download

05/11/10 - 1:00

The BoD approves Q3'10 results (414.16 KB)
Financial Data
Download

02/11/10 - 1:00

Change in share capital (313.61 KB)
Financial Data
Download

08/10/10 - 2:00

2010 Financial calendar update (174.1 KB)
Financial Data
Download

30/09/10 - 2:00

Change in share capital (5.25 KB)
Financial Data
Download

24/09/10 - 2:00

Financial instruments to employees (48.81 KB)
Financial Data
Download

16/09/10 - 2:00

Stock options exercised by key managers (195.67 KB)
Financial Data
Download

02/09/10 - 2:00

Financial instruments to employees (24.27 KB)
Financial Data
Download

06/08/10 - 2:00

The BoD approves H1'10 results (287.11 KB)
Financial Data
Download

06/07/10 - 2:00

2010 Financial calendar update (174.1 KB)
Financial Data
Download

02/07/10 - 2:00

Financial instruments to employees (24.37 KB)
Financial Data
Download

14/05/10 - 2:00

The BoD approves Q1'10 results (254.05 KB)
Financial Data
Download

27/04/10 - 2:00

Approval of statutory financial statements (182.99 KB)
Financial Data
Download

20/04/10 - 2:00

2010 Financial calendar update (168.23 KB)
Financial Data
Download

14/04/10 - 2:00

Postponement of the term for lists of members of the Board of Auditors (40.34 KB)
Financial Data
Download

09/04/10 - 2:00

China approves new prenatal screening product line on LIAISON (141.08 KB)
Products Immunodiagnostic
Download

02/04/10 - 2:00

Financial instruments to employees (27.79 KB)
Financial Data
Download

22/03/10 - 1:00

The BoD approves FY 2009 results (306.02 KB)
Financial Data
Download

01/03/10 - 1:00

2010 Financial calendar update (192.49 KB)
Financial Data
Download

12/02/10 - 1:00

The BoD approves Q4'09 results (213.8 KB)
Financial Data
Download

18/01/10 - 1:00

2010 Financial calendar (103 KB)
Financial Data
Download

24/12/09 - 1:00

Financial instruments to employees (26.76 KB)
Financial Data
Download

30/10/09 - 1:00

The BoD approves Q3'09 results (212.92 KB)
Financial Data
Download

08/10/09 - 2:00

2009 Financial calendar update (97.3 KB)
Financial Data
Download

05/10/09 - 2:00

Financial instruments to employees (27.08 KB)
Financial Data
Download

06/08/09 - 2:00

The BoD approves H1'09 results (214.79 KB)
Financial Data
Download

08/06/09 - 2:00

2009 Financial calendar update (97.33 KB)
Financial Data
Download

18/05/09 - 2:00

Financial instruments to employees (26.65 KB)
Financial Data
Download

10/04/09 - 2:00

Corporate Governance Report at December 2008. (97.57 KB)
Financial Data
Download

08/04/09 - 2:00

2009 Financial calendar update (103.88 KB)
Financial Data
Download

19/03/09 - 1:00

The BoD approves FY 2008 results (221.59 KB)
Financial Data
Download

20/02/09 - 1:00

Financial instruments to employees (26.39 KB)
Financial Data
Download

13/02/09 - 1:00

The BoD approves Q4'08 results (170.79 KB)
Financial Data
Download

28/01/09 - 1:00

2009 Financial calendar (93.96 KB)
Financial Data
Download

08/01/09 - 1:00

FDA clearance to five LIAISON products (96.84 KB)
Products Immunodiagnostic
Download

23/12/08 - 1:00

Financial instruments to employees (26.19 KB)
Financial Data
Download

21/11/08 - 1:00

Financial instruments to employees (23.66 KB)
Financial Data
Download

13/11/08 - 1:00

The BoD approves Q3'08 results (171.93 KB)
Financial Data
Download

08/08/08 - 2:00

The BoD approves H1'08 results (194.3 KB)
Financial Data
Download

16/05/08 - 2:00

Financial instruments to employees (23.28 KB)
Financial Data
Download

15/05/08 - 2:00

Results for Q1'08 (159.78 KB)
Financial Data
Download

24/04/08 - 2:00

2007 statutory financial Statements approved (93.67 KB)
Financial Data
Download

21/04/08 - 2:00

2008 Financial calendar update (93.56 KB)
Financial Data
Download

19/03/08 - 1:00

The BoD approves FY 2007 results (198.25 KB)
Financial Data
Download

14/02/08 - 1:00

The BoD approves Q4'07 results (170.91 KB)
Financial Data
Download

29/01/08 - 1:00

2008 Financial calendar (88.78 KB)
Financial Data
Download

07/01/08 - 1:00

Financial instruments to employees (29.51 KB)
Financial Data
Download
Price Sensitive

eMarket SDIR System and eMarket STORAGE
For the dissemination and the storage of Regulated Information, DiaSorin S.p.A. uses the eMarket SDIR circuit and the eMarket STORAGE mechanism (available at the address www.emarketstorage.it), managed by Teleborsa S.r.l., with registered office in Piazza di Priscilla, 4, Rome, Italy.